Dr Christine Martin - Head of Investment (Life Sciences)
As Head of Life Science investment, Christine works to help create companies across the breadth of the life sciences, with a focus on drug discovery. She works with a broad portfolio, including University of Cambridge spin-outs Pharmenable, Spirea, Carrick Therapeutics, STORM Therapeutics, Z-factor, PhoreMost, Qkine and PolyProX.
Christine has extensive experience in all stages of the investment process including due diligence, deal negotiation and investment management. She currently sits on the board of five portfolio companies as well as being an observer for another three.
Previously, Christine worked for six years in the Cambridge Enterprise Life Sciences Technology Transfer team managing the licensing of University IP. Christine also managed the University of Cambridge-GSK open innovation drug discovery initiative based at the Stevenage Bioscience Catalyst, working closely with academics to gain funding to develop translational projects.
Prior to joining Cambridge Enterprise, Christine enjoyed 11 years working at Biotica, a University spin-out.
Christine has an MA and DPhil from the University of Oxford, has authored over 20 peer-reviewed journal articles and is an inventor on over 20 patents. She was the recipient of the Arthur E. Schwarting award in 2006 and featured in BioBeat’s 50 Movers and Shakers in BioBusiness 2018.
Christine joined Cambridge Enterprise in September 2011.